JP2019505486A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019505486A5 JP2019505486A5 JP2018530079A JP2018530079A JP2019505486A5 JP 2019505486 A5 JP2019505486 A5 JP 2019505486A5 JP 2018530079 A JP2018530079 A JP 2018530079A JP 2018530079 A JP2018530079 A JP 2018530079A JP 2019505486 A5 JP2019505486 A5 JP 2019505486A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- osteoarthritis
- subject
- composition according
- cartilage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562264682P | 2015-12-08 | 2015-12-08 | |
| US62/264,682 | 2015-12-08 | ||
| PCT/US2016/065520 WO2017100400A2 (en) | 2015-12-08 | 2016-12-08 | Use of c-type natriuretic peptide variants to treat osteoarthritis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019505486A JP2019505486A (ja) | 2019-02-28 |
| JP2019505486A5 true JP2019505486A5 (https=) | 2020-01-23 |
| JP7104625B2 JP7104625B2 (ja) | 2022-07-21 |
Family
ID=59013378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018530079A Active JP7104625B2 (ja) | 2015-12-08 | 2016-12-08 | 骨関節炎を処置するためのｃ型ナトリウム利尿ペプチド変異体の使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11202819B2 (https=) |
| EP (2) | EP4019038A3 (https=) |
| JP (1) | JP7104625B2 (https=) |
| KR (1) | KR102941538B1 (https=) |
| CN (1) | CN108697766A (https=) |
| AU (2) | AU2016365751B2 (https=) |
| CA (1) | CA3007315A1 (https=) |
| DK (1) | DK3386531T3 (https=) |
| ES (1) | ES2901769T3 (https=) |
| HR (1) | HRP20211908T1 (https=) |
| HU (1) | HUE057083T2 (https=) |
| IL (1) | IL259690B2 (https=) |
| MX (1) | MX2018006986A (https=) |
| PL (1) | PL3386531T3 (https=) |
| PT (1) | PT3386531T (https=) |
| RU (1) | RU2759679C2 (https=) |
| WO (1) | WO2017100400A2 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3007976C (en) | 2016-01-08 | 2023-09-26 | Ascendis Pharma Growth Disorders A/S | Cnp prodrugs with large carrier moieties |
| ES3064816T3 (en) | 2016-01-08 | 2026-04-29 | Ascendis Pharma Growth Disorders As | Controlled-release cnp agonists with reduced side-effects |
| WO2017118700A1 (en) | 2016-01-08 | 2017-07-13 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with increased nep stability |
| EP3400021A1 (en) | 2016-01-08 | 2018-11-14 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with low npr-c binding |
| DK3400019T3 (da) | 2016-01-08 | 2022-10-24 | Ascendis Pharma Growth Disorders As | CNP-prodrugs med bærerbinding ved ringenheden |
| IL259827B2 (en) | 2016-01-08 | 2025-07-01 | Ascendis Pharma Growth Disorders As | Controlled-release CNP agonists with low initial NPR-B activity |
| US11564974B2 (en) | 2016-09-29 | 2023-01-31 | Ascendis Pharma Growth Disorders A/S | Combination therapy with controlled-release CNP agonists |
| BR112020021966A2 (pt) * | 2018-04-27 | 2021-01-26 | Remy Biosciences, Inc. | dispositivos médicos, veículos de liberação e fabricação dos mesmos |
| MX2021008708A (es) * | 2019-02-11 | 2021-09-21 | Ascendis Pharma Growth Disorders As | Formulaciones farmaceuticas secas de conjugados de peptido natriuretico tipo c (cnp). |
| WO2022115563A1 (en) * | 2020-11-25 | 2022-06-02 | Prolynx Llc | Extended release hydrogel conjugates of c-natriuretic peptides |
| US20240238428A1 (en) * | 2021-05-11 | 2024-07-18 | Texas Tech University System | Targeted selenium conjugates as countermeasures for viral and cellular pathogens |
| EP4444341A1 (en) * | 2021-12-07 | 2024-10-16 | BioMarin Pharmaceutical Inc. | C-type natriuretic peptide therapy of bone-related disorders |
| WO2024094747A1 (en) | 2022-11-02 | 2024-05-10 | Novo Nordisk A/S | Cnp compounds |
| WO2024104922A1 (en) | 2022-11-14 | 2024-05-23 | Ascendis Pharma Growth Disorders A/S | Method of improving skeletal muscle function |
| AU2024240722A1 (en) | 2023-03-20 | 2025-09-18 | Ascendis Pharma Growth Disorders A/S | Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia |
| KR20250098109A (ko) * | 2023-12-21 | 2025-07-01 | 주식회사 펩트론 | 나트륨이뇨 펩타이드 유사체 및 이의 용도 |
| CN117801123B (zh) * | 2024-02-29 | 2024-05-03 | 天津凯莱英生物科技有限公司 | 沃索利肽可溶性中间体、中间体制备方法及沃索利肽的制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| JP2809533B2 (ja) | 1991-01-31 | 1998-10-08 | 壽之 松尾 | Ｃｎｐ類似体ペプチド |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| IL142118A0 (en) | 2001-03-20 | 2002-03-10 | Prochon Biotech Ltd | Method and composition for treatment of skeletal dysplasias |
| ES2465141T3 (es) * | 2004-03-31 | 2014-06-05 | Kazuwa Nakao | Remedio o medicamento preventivo para la artritis |
| WO2005094890A1 (ja) * | 2004-03-31 | 2005-10-13 | Kazuwa Nakao | 身長増加用組成物 |
| EP2217620A2 (en) * | 2007-11-21 | 2010-08-18 | BioMarin Pharmaceutical Inc. | Variants of c-type natriuretic peptide |
| PT2432489T (pt) | 2009-05-20 | 2016-12-07 | Biomarin Pharm Inc | Variantes do péptido natriurético de tipo c |
| WO2012088608A1 (en) * | 2010-12-27 | 2012-07-05 | Enobia Canada Limited Partnership | Compositions comprising natriuretic peptides and methods of use thereof |
-
2016
- 2016-12-08 HU HUE16852866A patent/HUE057083T2/hu unknown
- 2016-12-08 EP EP21202207.3A patent/EP4019038A3/en active Pending
- 2016-12-08 US US15/779,049 patent/US11202819B2/en active Active
- 2016-12-08 ES ES16852866T patent/ES2901769T3/es active Active
- 2016-12-08 KR KR1020187019166A patent/KR102941538B1/ko active Active
- 2016-12-08 AU AU2016365751A patent/AU2016365751B2/en active Active
- 2016-12-08 PL PL16852866T patent/PL3386531T3/pl unknown
- 2016-12-08 RU RU2018124600A patent/RU2759679C2/ru active
- 2016-12-08 EP EP16852866.9A patent/EP3386531B1/en active Active
- 2016-12-08 CA CA3007315A patent/CA3007315A1/en active Pending
- 2016-12-08 HR HRP20211908TT patent/HRP20211908T1/hr unknown
- 2016-12-08 JP JP2018530079A patent/JP7104625B2/ja active Active
- 2016-12-08 CN CN201680081329.2A patent/CN108697766A/zh active Pending
- 2016-12-08 DK DK16852866.9T patent/DK3386531T3/da active
- 2016-12-08 WO PCT/US2016/065520 patent/WO2017100400A2/en not_active Ceased
- 2016-12-08 MX MX2018006986A patent/MX2018006986A/es unknown
- 2016-12-08 PT PT168528669T patent/PT3386531T/pt unknown
-
2018
- 2018-05-29 IL IL259690A patent/IL259690B2/en unknown
-
2021
- 2021-12-03 US US17/541,992 patent/US12214015B2/en active Active
-
2024
- 2024-03-21 AU AU2024201852A patent/AU2024201852A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019505486A5 (https=) | ||
| RU2018124600A (ru) | Применение вариантов натрийуретического пептида типа с для лечения остеоартрита | |
| Krishnan et al. | Cartilage diseases | |
| JP6431082B2 (ja) | Ｆｇｆ−１８化合物の投与計画 | |
| JP2016512552A (ja) | リツキシマブ導入療法とその後の酢酸グラチラマー療法 | |
| Voulgari et al. | Infliximab therapy in established rheumatoid arthritis: an observational study | |
| JP6208763B2 (ja) | 変形性関節症を治療するためのｐｅｄｆ−由来のポリペプチドの使用 | |
| Nakamagoe et al. | Polymyalgia rheumatica in a melanoma patient due to nivolumab treatment | |
| JP7012383B2 (ja) | 関節痛を緩和する方法 | |
| CN107661501A (zh) | 一种治疗强直性脊柱炎的药物组合物、药物靶点及其应用 | |
| Sofat et al. | Recent clinical evidence for the treatment of osteoarthritis: what we have learned | |
| CN119546340A (zh) | 使用白细胞介素-17（il-17）拮抗剂选择性治疗肌腱病的方法 | |
| EP3865179B1 (en) | Hmgb1 derived peptide for treating or preventing a cartilage disorder | |
| TWI491407B (zh) | 色素上皮衍生因子衍生之多胜肽於治療骨性關節炎之用途 | |
| JP2021523894A5 (https=) | ||
| Fernandez et al. | Review of the novelties presented at the 2018 ECTRIMS Congress: 11th Post-ECTRIMS Meeting (II) | |
| US20180236032A1 (en) | Combination composition comprising fgf-18 compound | |
| Mohanan et al. | IGURATIMOD: A NOVEL SMALL MOLECULE DISEASE-MODIFYING ANTIRHEUMATIC DRUG FOR SEROPOSITIVE RHEUMATOID ARTHRITIS-A PROSPECTIVE OBSERVATIONAL STUDY | |
| Jayashankar et al. | An uncommon variant of rare type of muscular dystrophy | |
| Živković | Relapsing polychondritis: From etiopathogenesis to therapy | |
| WO2020257173A1 (en) | Method of treating the osteoarthritic joint | |
| Komlos | American College of Rheumatology/Association of Rheumatology Professionals (ACR/ARP) Annual Meeting (ACR Convergence 2020). Virtual-November 5-9, 2020 | |
| HK40060107A (en) | Hmgb1 derived peptide for treating or preventing a cartilage disorder | |
| NZ745815A (en) | Methods of treatment | |
| HK40060107B (en) | Hmgb1 derived peptide for treating or preventing a cartilage disorder |